Al-Alem, Linah
Prendergast, Jillian M.
Clark, Justin
Zarrella, Bianca
Zarrella, Dominique T.
Hill, Sarah J.
Growdon, Whitfield B.
Pooladanda, Venkatesh
Spriggs, David R.
Cramer, Daniel
Elias, Kevin M.
Nazer, Rawan I.
Skates, Steven J.
Behrens, Jeff
Dransfield, Daniel T.
Rueda, Bo R.
Funding for this research was provided by:
Nile Albright Research Foundation (N/A, N/A, N/A, N/A, N/A, N/A)
Vincent Memorial Hospital Foundation (N/A, N/A, N/A, N/A, N/A, N/A)
National Cancer Institute (NCI) of the National Institutes of Health (NIH) Small Business Innovation Research (HHSN261200700063C, HHSN261200700063C, HHSN261200700063C, HHSN261200700063C, HHSN261200700063C)
National Institutes of Health (NIH 1DP5OD029637)
U.S. Department of Defense (DOD OCRP Pilot OC180061)
Tina’s Wish Rising Star Award (N/A)
NCI Early Detection Research Network Grants (CA152990)
NCI Early Detection Research Network (U2C-CA271871)
Concord (MA) Detect Ovarian Cancer Early Fund
Article History
Received: 24 August 2023
Accepted: 21 March 2024
First Online: 2 April 2024
Declarations
:
: As stated above all primary patient samples used herein were derived either from patients who provided written informed consent or were collected on an institutional IRB approved protocol allowing for use of discarded tissue. All samples were coded and therefore we have no direct access to patient health identifiers as per our IRB protocol.
: Not Applicable.
: This research led to the development of products that were previously owned by or licensed to Siamab Therapeutics, Inc. in which JMP, RIN, DTD, JB had a business and/or financial interest. BRR served as a consultant for SIAMAB Therapeutics.